BASF plans significant investment in ibuprofen capacities in Germany and North America
New world-scale ibuprofen production plant in Ludwigshafen; additional capacity expansion of ibuprofen plant in Bishop, Texas.
BASF plans to build a new world-scale plant to produce ibuprofen in Ludwigshafen, Germany.The new plant, is scheduled to come onstream in 2021. “It will be the first world-scale ibuprofen plant in Europe,” says Dr Markus Kamieth, Member of the Board of Executive Directors, BASF SE. With this investment, BASF aims to ensure high supply security for its customers and meet growing global demand.
BASF is also expanding its ibuprofen capacities at its production site in Bishop, Texas, to fill current supply gaps for ibuprofen in the market. The expansion will come onstream in early 2018. The company will invest approximately €200 million in both projects.
“BASF will be the only supplier with two ibuprofen assets worldwide. This makes us a highly reliable partner for our customers,” says Kamieth.
“Both investments show our strong commitment to the pharmaceutical industry and our pharma solutions business,” says Dr Melanie Maas-Brunner, President of BASF’s Nutrition & Health business. “They enable us to close supply gaps and efficiently support our customers’ growth plans.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.